Aspira Women's Health (AWH) Registration Filing summary

Company overview and business model

• Focuses on noninvasive, AI-powered diagnostic tests for gynecologic diseases, with initial emphasis on ovarian cancer and plans to expand to other gynecologic conditions.

• Commercializes products through a decentralized technology transfer platform, Aspira Synergy, and operates a CLIA-certified lab in Texas.

• Product pipeline includes OvaWatch and OVAinform for ovarian cancer and ENDOinform for endometriosis, targeting large addressable markets.

• Seeks to expand access among Medicaid patients and advocate for inclusion in professional guidelines.

Financial performance and metrics

• As of December 29, 2025, 43,480,411 shares of common stock were outstanding, with a closing price of $0.63 per share.

• The offering could increase outstanding shares to 59,353,427, excluding options and warrants.

• The company is a smaller reporting company, with market value of public float under $700 million and annual revenue under $100 million.

Use of proceeds and capital allocation

• May receive up to $10.0 million in gross proceeds from sales to Lincoln Park under the Purchase Agreement.

• Net proceeds, estimated at up to $9.9 million over 24 months, will be used for working capital and general corporate purposes, including R&D.

• Management has broad discretion over use of proceeds, which may be invested in short/intermediate-term instruments pending use.